T. Weidner, U. Paasch, S. Grunewald
Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete
Small molecules are rapidly broadening the spectrum of systemic oncologic therapies. Targets of those drugs are-among others-tyrosine and serine/threonine kinases like VEGF-R, EGF-R, Bcr-Abl, c‑kit, JAK, CDK as well as BRAF and MEK. Clinical data of potential risks to male fertility are still very limited and are generally only available for older preparations. In addition, they are often multikinase inhibitors, so that even small molecules with the same (main) target are not completely comparable. For fertility protection, sperm cryopreservation should be offered to men seeking fatherhood before starting targeted therapy.